Skip to main content
Clinical Trials/NCT04276012
NCT04276012
Unknown
Not Applicable

Effectiveness of a Cardiovascular Risk Intervention Program in Patients With Schizophrenia: PRISCA Study

Dr. Pere Roura-Poch1 site in 1 country130 target enrollmentJanuary 20, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
Dr. Pere Roura-Poch
Enrollment
130
Locations
1
Primary Endpoint
Changes in global cardiovascular risk
Last Updated
5 years ago

Overview

Brief Summary

The main objective is to determine the effectiveness of a program which consists of multidisciplinary, intensive and individualized interventions, carried out by a group of health professionals (psychiatrist, psychologist, mental health nurse, primary care doctors, pharmacist), during six-month, to improve the global cardiovascular risk (CVR) in patients with schizophrenia. Secondarily, will be analyzed the effectiveness of this program on improving the control in four selected cardiovascular risk factors: hypertension, hypercholesterolemia, hyperglycaemia and smoking, after 6 months Methods: randomized study with parallel assignment in two groups: control and intervention group, six-month follow-up. The eligible patients will be 130 adult (≥18 years) outpatients with a current diagnosis of schizophrenia who follow-up by health mental network in Catalonia, who presents at least bad control in one of the four selected cardiovascular risk factors. The intervention group will receive a multidisciplinary and individualized approach (psychoeducational, recommendations of life style and diet, medication adherence and changes in pharmacological strategy, depending on the individual needs assessing after cardiovascular risk screening. The control group will follow the standard management according to the primary care professionals' team.

Main measurements: the global CVR at baseline and at six-month follow-up through Framingham tables calibrated for the Catalan population (Registre Gironí del Cor, REGICOR). Secondary measures: they will be determined, at baseline and at six-month follow-up, four cardiovascular risk factors as well: hypertension, hypercholesterolemia, hyperglycaemia and smoking, according with the latest recommendations of the Program of preventive activities and health promotion (PAPPS) of the Spanish Society of Family and Community Medicine. Other measures: anthropometric parameters. Functional Assessment Screening Tool (FAST) and quality of life (EQ-5D).

Registry
clinicaltrials.gov
Start Date
January 20, 2020
End Date
February 28, 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Dr. Pere Roura-Poch
Responsible Party
Sponsor Investigator
Principal Investigator

Dr. Pere Roura-Poch

Epidemiologist

Consorci Hospitalari de Vic

Eligibility Criteria

Inclusion Criteria

  • adults (≥18 years of age), outpatient, current diagnostic of schizophrenia, follow-up by mental health network in Catalonia, signed informed consent.

Exclusion Criteria

  • other severe mental illnesses different from schizophrenia, patients with intellectual disabilities or clinical acute psychotic relapse

Outcomes

Primary Outcomes

Changes in global cardiovascular risk

Time Frame: At six months

Framingham tables calibrated for the Catalan population (Registre Gironí del Cor, REGICOR). The CVR was stratified into the following groups:\<5%, low; 5-9%, moderate; 10-14%, high; and ≥15, very high.

Secondary Outcomes

  • Stopping tobacco(At six months)
  • Changes in systolic/diastolic blood pressure(At six months)
  • Changes in cholesterolemia level and other lipids in blood(At six months)
  • Changes in glycated haemoglobin(At six months)

Study Sites (1)

Loading locations...

Similar Trials